Mumbai: Clinical trial of COVID-19 vaccine begins at KEM, Nair hospitals

Updated: 27 September, 2020 07:17 IST | A correspondent | Mumbai

While the screening process at both the hospitals had begun earlier, plans for clinical trials took a hit, after a participant became ill at the Oxford University, in the second week of September

KEM hospitals
KEM hospitals

Three candidates in the age group of 25 to 45 were given the first trial dose of COVID-19 vaccine, developed by the Oxford University and AstraZeneca, on Saturday at the King Edward Memorial (KEM) Hospital. With this, the clinical trial of COVID-19 began in Mumbai. BYL Nair will start trials on Monday.

The candidates, all male, were selected after screening of 13 volunteers. They have undergone screening and RT-PCR tests to rule out COVID positivity or any other health issues. The vaccine induces a strong immune response within 14 days of the dose, and an antibody response within 28 days. "The volunteers will be checked regularly and within 29 days, a second dose will be given to them," said an official from the BMC.

While the screening process at both the hospitals had begun earlier, plans for clinical trials took a hit, after a participant became ill at the Oxford University, in the second week of September. Later, DCGI gave its nod to conduct the second and third phase of the trial.

Keep scrolling to read more news

Catch up on all the latest Mumbai news, crime news, current affairs, and a complete guide from food to things to do and events across Mumbai. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news</p

First Published: 27 September, 2020 07:20 IST

Sign up for all the latest news, top galleries and trending videos from Mid-day.com

Subscribe
loading image
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK